LNP Brain-Selective Cargo Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral delivery technologies, such as ionizable lipid nanoparticles (LNPs), have not been effectively studied for delivering nucleic acid cargo to the perinatal brain, particularly for in utero gene editing applications.
Innovation Solution
Development of a specific LNP composition comprising ionizable lipids, helper lipids, cholesterol, and nucleic acid cargo, including mRNA and sgRNA, which are partially encapsulated within the LNPs, optimized for efficient delivery to the perinatal brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ionizable lipid nanoparticles are used for delivering nucleic acid cargo to the perinatal brain, then delivery efficiency may be improved, but the technology has not been effectively studied and optimized for this specific application
Solution Approach 1:
The patent optimizes multiple parameters of the LNP composition including ionizable lipid structure (Formula I with specific R groups), helper lipid type (DOPE), cholesterol content (40-60 mol%), and nucleic acid to lipid ratios to achieve efficient brain delivery. The ionizable lipid's pKa and hydrophobic tail length are specifically tuned for perinatal brain targeting.
Solution Approach 2:
The LNP composition is designed to serve multiple functions: protecting nucleic acid cargo from degradation, facilitating cellular uptake, enabling endosomal escape, and specifically targeting the perinatal brain. The same LNP formulation delivers both mRNA and sgRNA for coordinated gene editing function.
2Manufacturing precision
If a complex LNP composition is developed for brain-selective delivery, then delivery precision is improved, but the device complexity increases
Solution Approach 1:
The LNP composition is specifically engineered with local quality for brain targeting: ionizable lipids with specific hydrophobic tail lengths (C12-C24), particular helper lipids (DOPE, DSPC), and optimized cholesterol content (40-60 mol%) create a formulation that selectively accumulates in the perinatal brain while minimizing off-target delivery to other organs.
Solution Approach 2:
The patent employs a composite LNP material system combining ionizable lipids (Formula I), helper lipids (DOPE, DSPC), cholesterol, and nucleic acid cargo. This composite structure leverages the complementary properties of each component: ionizable lipids for endosomal escape, DOPE for membrane fusion, cholesterol for stability, and nucleic acids for therapeutic function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized LNP composition achieves effective mRNA delivery and base editing in the perinatal brain, demonstrating potential for treating congenital brain diseases through in utero gene editing.
Implementation Method 1
a lipid nanoparticle (LNP) composition comprises at least one ionizable lipid, at least one helper lipid, cholesterol, and at least one conjugated lipid, and nucleic acid cargo comprising at least one mRNA and at least one sgRNA
Data Source
AI summary
In one aspect, the present disclosure relates to lipid nanoparticles (LNPs) comprising at least one ionizable lipid, at least one helper lipid, cholesterol, at least one conjugated lipid, and at least one nucleic acid cargo (e.g., at least one mRNA and at least one sgRNA). In another aspect, the present disclosure relates to a method of delivering a cargo to the brain of a subject in need thereof. In another aspect, the present disclosure relates to methods of genome editing a mutated gene sequence associated with a disease or disorder in a subject in need thereof. In another aspect, the present disclosure relates to methods of treating a lysosomal storage disease in a subject in need thereof. In certain embodiments, the LNPs of the present disclosure are administrated in utero and/or intracerebroventricularly. In certain embodiments, the subject is embryonic, fetal, neonatal, or perinatal.